Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
Brief Summary: The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS SR versus placebo in subjects with Major Depressive Disorder. Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject.


Options:
A: Inclusion Criteria:

1. 18 - 60 years
2. Major depression according to DSM-IV
3. Living within 30 km of training facilities
4. Able to read and understand informed consent

Exclusion Criteria:

1. Recreational or current drug abuse
2. Having used antidepressant medication within the last 2 months
3. Contraindications to physical exercise
4. Recreational exercise\> 1 hour per week
5. Medication for diabetes, hypertension, or any kidney disease
6. Suicidal behaviour (ham-d17 item3 \> 2)
B: Inclusion Criteria:

* Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by DSM-IV-TR criteria
* The current depressive episode must be equal to or greater than 8 weeks in duration
* Subjects must report a history for the current depressive episode of an inadequate response to at least one and no more than three adequate antidepressant treatments.

Exclusion Criteria:

* Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug.
* Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration.
* Subjects with a current Axis I (DSM-IV-TR) diagnosis of:

  * Delirium, dementia,amnestic or other cognitive disorder
  * Schizophrenia, schizoaffective disorder, or other psychotic disorder
  * Bipolar I or II disorder
  * Subjects with a clinically significant current Axis II (DSM-IV-TR)
  * diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.
C: Inclusion Criteria:

* A primary diagnosis of MDD
* Depressive symptoms for at least 30 days before the screening visit.

Exclusion Criteria:

* Treatment with DVS SR at any time in the past.
* Known hypersensitivity to venlafaxine
* Significant risk of suicide based on clinical judgment
D: Inclusion Criteria:

* Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by DSM-IV-TR criteria
* The current depressive episode must be equal to or greater than 8 weeks in duration
* Subjects must report a history for the current depressive episode of an inadequate response to no more than three adequate antidepressant treatments

Exclusion Criteria:

* Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug
* Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration
* Subjects with a current Axis I (DSM-IV-TR) diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder
* Subjects with a clinically significant current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder

Answer: C